Latest Articles
Leerink Raises Genmab (GMAB) Price Target, Keeps Outperform Rating - Insider Monkey
Leerink Raises Genmab (GMAB) Price Target, Keeps Outperform Rating Insider Monkey
Published: June 4, 2025, 9:54 p.m.
Musk, AI, and the Weaponization of 'Administrative Error' - Tech Policy Press
Musk, AI, and the Weaponization of 'Administrative Error' Tech Policy Press
Published: June 4, 2025, 12:45 p.m.
Blue Cross Collaborates with GBA Healthcare Institutions to Build an | - Business Post Nigeria
Blue Cross Collaborates with GBA Healthcare Institutions to Build an | Business Post Nigeria
Published: June 4, 2025, 5:32 a.m.
Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin - Frontiers
Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin Frontiers
Published: June 3, 2025, 6:52 p.m.
Julianne Hough Celebrates the 20th Anniversary of ‘Dancing With the Stars’ - EntertainmentNow
Julianne Hough Celebrates the 20th Anniversary of ‘Dancing With the Stars’ EntertainmentNow
Published: June 3, 2025, 1:05 p.m.
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer - Insider Monkey
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer Insider Monkey
Published: June 3, 2025, 5 a.m.
Aussie tradie dies in horror workplace accident while operating cherry picker near powerlines - Daily Mail
Aussie tradie dies in horror workplace accident while operating cherry picker near powerlines Daily Mail
Published: June 3, 2025, 1:30 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Link copied to clipboard!